Black Rock Inc. Achilles Therapeutics PLC Transaction History

Black Rock Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$2.26 - $3.38 $16,477 - $24,643	-7,291 Reduced 2.8%	253,112 $572,000
Q2 2022 Aug 12, 2022	SELL	$1.96 - $3.04 $12,257 - $19,012	-6,254 Reduced 2.35%	260,403 $656,000
Q1 2022 May 12, 2022	BUY	$2.8 - $5.23 $151,830 - $283,596	54,225 Added 25.53%	266,657 $784,000
Q4 2021 Feb 10, 2022	BUY	$4.22 - $8.86 $896,463 - $1.88 Million	212,432 New	212,432 $1.06 Million
Q3 2021 Nov 09, 2021	SELL	$5.81 - $9.93 $145,250 - $248,250	-25,000 Closed	0 $0
Q2 2021 Aug 11, 2021	BUY	$9.79 - $17.86 $244,749 - $446,500	25,000 New	25,000 $244,000

24.3M

Ticker ACHL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,774,000
Market Cap $47.3M
Description
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in ...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.